Director/PDMR Shareholding

RNS Number : 3980P

Oxford Biomedica PLC

07 February 2019

 

Director Dealings / Market Share Transactions

Oxford, UK - 07 February 2019: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Andrew Heath, Deputy Chairman and Senior Independent Director of the Group, purchased 972 ordinary shares of 50p each ("Ordinary Shares") in the Company on 06 February 2019 on the London Stock Exchange at a price of 715p and sold 981 Ordinary Shares on 06 February 2019 on the London Stock Exchange at a price of 713p in order to transfer the shares into his ISA.

Following this purchase and sale Dr. Andrew Heath holds 43,977 shares representing 0.07% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold and purchased.

1.	Details of the person discharging material responsibilities/person closely                 associated
a.	Name	Dr. Andrew Heath
2.	Reason for the notification
a.	Position/status	Deputy Chairman and Senior Independent Director
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford BioMedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford BioMedica plc Ordinary Shares of 50p each  GB00BDFBVT43
b.	Nature of the transaction	Purchase of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£7.15	972
e.	Aggregated information ·      Aggregated volume ·      Price ·      Aggregated total	972  £7.15  £6,949.80
f.	Date of the transaction	2019-02-06
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the person discharging material responsibilities/person closely                 associated
a.	Name	Dr. Andrew Heath
2.	Reason for the notification
a.	Position/status	Deputy Chairman and Senior Independent Director
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford BioMedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford BioMedica plc Ordinary Shares of 50p each  GB00BDFBVT43
b.	Nature of the transaction	Disposal of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£7.13	981
e.	Aggregated information ·      Aggregated volume ·      Price ·      Aggregated total	981  £7.13  £6,994.53
f.	Date of the transaction	2019-02-06
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

The issued share capital of the Group is 66,122,617 ordinary 50p shares.                      

-Ends-

For further information, please contact:
Oxford BioMedica plc: Stuart Paynter, Company Secretary	Tel: [phone]

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations and GC LabCell, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 360 people. Further information is available at www.oxb.com

 

END

 

 

DSHBBGDDISGBGCR